Wall Street brokerages expect Cellectis SA (NASDAQ:CLLS) to announce $1.93 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Cellectis’ earnings. The highest sales estimate is $3.00 million and the lowest is $500,000.00. Cellectis reported sales of $2.19 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 11.9%. The company is expected to issue its next quarterly earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that Cellectis will report full year sales of $12.24 million for the current fiscal year, with estimates ranging from $10.14 million to $14.00 million. For the next fiscal year, analysts expect that the business will post sales of $48.30 million, with estimates ranging from $15.00 million to $82.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Cellectis.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.18). Cellectis had a negative return on equity of 21.51% and a negative net margin of 813.06%. The business had revenue of $2.93 million during the quarter, compared to analysts’ expectations of $3.45 million.

CLLS has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a report on Monday, August 26th. Citigroup restated a “neutral” rating and issued a $22.00 target price on shares of Cellectis in a report on Friday, May 24th. BTIG Research initiated coverage on shares of Cellectis in a report on Friday, August 9th. They issued a “buy” rating and a $37.00 target price on the stock. Goldman Sachs Group set a $20.00 target price on shares of Cellectis and gave the company a “hold” rating in a report on Monday, August 12th. Finally, BidaskClub lowered shares of Cellectis from a “sell” rating to a “strong sell” rating in a report on Saturday, August 17th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $31.67.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC acquired a new stake in Cellectis during the 2nd quarter worth approximately $103,000. Aperio Group LLC acquired a new stake in Cellectis in the second quarter valued at approximately $147,000. A.R.T. Advisors LLC acquired a new stake in Cellectis in the second quarter valued at approximately $171,000. OneAscent Financial Services LLC acquired a new stake in Cellectis in the second quarter valued at approximately $257,000. Finally, Deutsche Bank AG grew its position in Cellectis by 178.8% in the fourth quarter. Deutsche Bank AG now owns 47,700 shares of the biotechnology company’s stock valued at $794,000 after acquiring an additional 30,589 shares in the last quarter. 32.30% of the stock is owned by institutional investors.

Shares of Cellectis stock traded up $0.07 on Tuesday, hitting $12.67. The company’s stock had a trading volume of 91,438 shares, compared to its average volume of 121,127. Cellectis has a 52-week low of $11.53 and a 52-week high of $29.40. The company has a quick ratio of 8.46, a current ratio of 8.47 and a debt-to-equity ratio of 0.11. The firm has a fifty day moving average price of $13.08 and a 200-day moving average price of $16.53. The company has a market capitalization of $527.14 million, a P/E ratio of -6.56 and a beta of 1.76.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Read More: Do closed-end mutual funds pay dividends?

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.